Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe
Businesswire·2025-12-01 06:00
Core Viewpoint - Samsung Bioepis Co., Ltd. has announced the launch of two denosumab biosimilars, OBODENCE and XBRYK, which reference Prolia and Xgeva, set to be commercially available in Europe by December 2025 and January 2026 respectively [1] Group 1 - OBODENCE is a 60 mg pre-filled syringe biosimilar, while XBRYK is a 120 mg vial biosimilar [1] - The launch aims to address the significant challenge of osteoporosis treatment in Europe, where there are limited options and affordability issues [1]